Xenon Pharmaceuticals (XENE) to Release Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) is projected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Xenon Pharmaceuticals to post earnings of ($0.89) per share and revenue of $0.31 million for the quarter.

Xenon Pharmaceuticals Price Performance

XENE opened at $39.73 on Friday. The business has a fifty day moving average price of $39.45 and a 200 day moving average price of $40.40. Xenon Pharmaceuticals has a 12 month low of $35.53 and a 12 month high of $50.99. The stock has a market capitalization of $3.03 billion, a price-to-earnings ratio of -14.09 and a beta of 1.20.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price target for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $57.38.

Insider Activity

In other news, CFO Sherry Aulin sold 18,709 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Ian Mortimer sold 22,468 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $40.20, for a total transaction of $903,213.60. Following the completion of the sale, the chief executive officer now owns 31,302 shares of the company’s stock, valued at approximately $1,258,340.40. This trade represents a 41.79 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,492 shares of company stock worth $2,334,969. Corporate insiders own 5.52% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.